Fdc Ltd. (BSE: 531599) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹5,807 Cr, it ranks #790 by market cap among the 6,137 Indian listed companies on FinBizNet, and #24 of 86 in Medicinal Chemicals and Botanical Products. At ₹338.70 (as of 25 Oct 2026), the share price is 28.5% below its 52-week high of ₹473.60 and 8.2% above its 52-week low of ₹312.95. The share price is down 22.3% over one year and down 18.0% over three months.
| Current Price | ₹338.70 |
|---|---|
| Market Cap | ₹5,807 Cr |
| BSE Code | 531599 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 19.9 |
| Return on Equity | 11.81% |
| Return on Assets | 6.37% |
| 52-Week Range | ₹312.95 – ₹473.60 |
| 1-Year Price Change | -22.3% |
| 3-Month Price Change | -18.0% |
| Beta (1Y) | 0.24 |
| Dividend Yield | 2.91% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.fdcindia.com |
| Revenue | ₹668 Cr |
|---|---|
| Net Profit | ₹132 Cr |
| Net Margin | 19.8% |
| EPS (Basic) | ₹8.14 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to app
1. Pharmaceuticals-This segment engages in the pharmaceutical business.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Fdc Ltd. | ₹5,807 Cr | 19.9 | 11.81% | ₹668 Cr | -22.3% |
Listed by market capitalisation. Ratios are shown for context only.
Fdc Ltd. is trading at ₹338.70, with a market capitalisation of ₹5,807 Cr.
Fdc Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Fdc Ltd. has a P/E of 19.9 and a return on equity of 11.81%.
Fdc Ltd. is listed on the BSE under the scrip code 531599.
Fdc Ltd.'s share price is down 22.3% over one year and down 18.0% over three months. Its 52-week range is ₹312.95 to ₹473.60.
In Q1 FY27, Fdc Ltd. reported revenue of ₹668 Cr and net profit of ₹132 Cr, with basic EPS of ₹8.14 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.